ES2565345T3 - Nuevos inhibidores de la reductasa de s-nitrosoglutatión - Google Patents

Nuevos inhibidores de la reductasa de s-nitrosoglutatión Download PDF

Info

Publication number
ES2565345T3
ES2565345T3 ES11742796.3T ES11742796T ES2565345T3 ES 2565345 T3 ES2565345 T3 ES 2565345T3 ES 11742796 T ES11742796 T ES 11742796T ES 2565345 T3 ES2565345 T3 ES 2565345T3
Authority
ES
Spain
Prior art keywords
group
formula
new
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11742796.3T
Other languages
English (en)
Inventor
Xicheng Sun
Jian Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nivalis Therapeutics Inc
Original Assignee
Nivalis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nivalis Therapeutics Inc filed Critical Nivalis Therapeutics Inc
Application granted granted Critical
Publication of ES2565345T3 publication Critical patent/ES2565345T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El compuesto de formula (I)**Fórmula** o una sal farmaceuticamente aceptable del mismo, en la que X se selecciona de entre el grupo que consiste en O y S; Y se selecciona de entre el grupo que consiste en O y S; Z se selecciona de entre el grupo que consiste en Z1, Z2, Z3 y Z4, en donde Z1 es**Fórmula** Z2 es**Fórmula** Z3 es**Fórmula** y Z4 es**Fórmula** con la condicion de que Z unicamente es Z4 cuando al menos uno de X o Y es S; R1 se selecciona de entre el grupo que consiste en hidrogeno, alquilo (C1-C6), cicloalquilo (C3-C7), haloalquilo (C1-C6), arilalquilo (C1-C4) no sustituido, arilalquilo (C1-C6) sustituido, heteroalquilo (C1-C6), arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido; R2 se selecciona de entre el grupo que consiste en hidrogeno, halogeno, ciano y alcoxi (C1-C6); R3 se selecciona de entre el grupo que consiste en hidrogeno, halogeno, alquilo (C1-C6), haloalquilo (C1-C6), alcoxi (C1-C6), ciano y N,N-dimetilamino; R4 se selecciona de entre el grupo que consiste en tetrazol, oxadiazolona, tiadiazolona, metilsulfonilcarbamoilo y N-hidroxicarbamoilo; y R5 se selecciona de entre el grupo que consiste en carboxi, tetrazol, oxadiazolona, tiadiazolona, metilsulfonilcarbamoilo y N-hidroxicarbamoilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
5
15
25
35
45
55
65
antibacterianos tales como alcohol bencílico o metilparabenos; (3) antioxidantes tales como ácido ascórbico o bisulfito de sodio; (4) agentes quelantes tales como ácido etilendiaminotetraacético; (5) tampones tales como acetatos, citratos o fosfatos; y (5) agentes para el ajuste de la tonicidad tales como cloruro de sodio o dextrosa. El pH puede ajustarse con ácidos o con bases, tales como ácido clorhídrico o hidróxido de sodio. Una preparación parenteral puede estar contenida en ampollas, en jeringas desechables o en viales de dosis múltiples hechos de vidrio o de plástico.
Las composiciones farmacéuticas adecuadas para su uso inyectable pueden comprender soluciones o dispersiones acuosas estériles (cuando sean solubles en agua) y polvos estériles para la preparación extemporánea de soluciones o de dispersiones inyectables estériles. Para la administración intravenosa, algunos vehículos adecuados incluyen solución salina fisiológica, agua bacteriostática, Cremophor EL (BASF, Parsippany, N.J.), o solución salina tamponada con fosfato (PBS). En todos los casos, la composición debe ser estéril y debe ser fluida hasta el punto de que exista una fácil jeringabilidad. La composición farmacéutica debe ser estable en las condiciones de elaboración y de almacenamiento, y debe preservarse frente a la acción contaminante de microorganismos tales como bacterias y hongos.
El vehículo puede ser un disolvente o un medio de dispersión que comprende, por ejemplo, agua, etanol, un poliol (por ejemplo, glicerol, propilenglicol y polietilenglicol líquido y similares) y mezclas adecuadas de los mismos. La fluidez apropiada puede mantenerse, por ejemplo, mediante el uso de un recubrimiento tal como lecitina, mediante el mantenimiento del tamaño de partícula requerido en el caso de una dispersión, y mediante el uso de tensioactivos. La prevención de la acción de los microorganismos puede conseguirse mediante diversos agentes antibacterianos y antifúngicos, por ejemplo, parabenos, clorobutanol, fenol, ácido ascórbico, timerosal y similares. En muchos casos será preferible incluir en la composición agentes isotónicos, por ejemplo, azúcares, polialcoholes tales como manitol
o sorbitol, y sales inorgánicas tales como cloruro de sodio. La absorción prolongada de las composiciones inyectables puede conseguirse mediante la inclusión en la composición de un agente que retarde la absorción, por ejemplo, monoestearato de aluminio y gelatina.
Las soluciones inyectables estériles pueden ser preparadas mediante la incorporación del reactivo activo en la cantidad requerida en un disolvente apropiado con uno o una combinación de los ingredientes enumerados anteriormente, según se requiera, seguido de una esterilización por filtración. Generalmente, las dispersiones se preparan mediante la incorporación de al menos un compuesto de la invención en un vehículo estéril que contiene un medio de dispersión básico y cualquier otro ingrediente requerido. En el caso de los polvos estériles para la preparación de soluciones inyectables estériles, algunos métodos a modo de ejemplo de preparación incluyen secado a vacío y liofilización, produciendo ambos un polvo de un compuesto de la invención más cualquier ingrediente adicional deseado a partir de una solución previamente filtrada estéril de los mismos.
Las composiciones orales incluyen generalmente un diluyente inerte o un vehículo comestible. Pueden estar incluidas, por ejemplo, en cápsulas de gelatina, o comprimidas en comprimidos. Con el fin de una administración terapéutica oral, el compuesto de la invención puede ser incorporado con excipientes y usado en forma de comprimidos, de tabletas o de cápsulas. Las composiciones orales también pueden prepararse mediante el uso de un vehículo fluido para su uso como un enjuague bucal, en el que el compuesto del vehículo fluido se aplica por vía oral y se enjuaga y se expectora o se ingiere. Como parte de la composición pueden incluirse agentes ligantes y/o materiales adyuvantes farmacéuticamente compatibles.
Para una administración mediante inhalación, los compuestos son administrados en forma de un nebulizador de aerosol desde un recipiente presurizado o un dispensador que contiene un propulsor adecuado, por ejemplo, un gas tal como dióxido de carbono, un líquido nebulizado o un polvo seco desde un dispositivo adecuado. Para una administración transmucosal o transdérmica, en la formulación se usan unos penetrantes apropiados para la barrera que va ser atravesada. Dichos penetrantes son conocidos generalmente en la técnica, e incluyen, por ejemplo, para una administración transmucosal, detergentes, sales biliares y derivados del ácido fusídico. La administración transmucosal puede llevarse a cabo mediante el uso de aerosoles nasales o de supositorios. Para la administración transdérmica, los reactivos activos se formulan en ungüentos, bálsamos, geles o cremas, como se sabe de forma general en la técnica. Los reactivos también pueden prepararse en forma de supositorios (por ejemplo, con bases para supositorios convencionales tales como manteca de cacao y otros glicéridos) o enemas de retención para su administración rectal.
En una forma de realización, los compuestos de la invención se preparan con vehículos que los protegerán frente una rápida eliminación desde el cuerpo. Por ejemplo, puede usarse una formulación de liberación controlada, incluyendo implantes y sistemas de administración microencapsulados. Pueden usarse polímeros biodegradables biocompatibles, tales como etilenacetato de vinilo, polianhídridos, ácido poliglicólico, colágeno, poliortoésteres y ácido poliláctico. Los métodos para la preparación de dichas formulaciones serán evidentes para los expertos en la técnica.
También pueden usarse suspensiones liposómicas (incluyendo liposomas dirigidos a las células infectadas con anticuerpos monoclonales contra los antígenos víricos) como vehículos farmacéuticamente aceptables. Éstos pueden prepararse de acuerdo con los métodos conocidos por los expertos en la técnica, por ejemplo, según se
14
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES11742796.3T 2010-02-12 2011-02-10 Nuevos inhibidores de la reductasa de s-nitrosoglutatión Active ES2565345T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30395210P 2010-02-12 2010-02-12
US303952P 2010-02-12
PCT/US2011/024353 WO2011100433A1 (en) 2010-02-12 2011-02-10 Novel s-nitrosoglutathione reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2565345T3 true ES2565345T3 (es) 2016-04-04

Family

ID=44368117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11742796.3T Active ES2565345T3 (es) 2010-02-12 2011-02-10 Nuevos inhibidores de la reductasa de s-nitrosoglutatión

Country Status (21)

Country Link
US (3) US8759548B2 (es)
EP (1) EP2533638B1 (es)
JP (2) JP5878484B2 (es)
KR (1) KR20120138746A (es)
CN (1) CN102869255B (es)
AU (1) AU2011215833B2 (es)
BR (1) BR112012019529A2 (es)
CA (1) CA2787633A1 (es)
DK (1) DK2533638T3 (es)
ES (1) ES2565345T3 (es)
HK (1) HK1178742A1 (es)
HR (1) HRP20160450T1 (es)
HU (1) HUE029012T2 (es)
IL (1) IL220956A (es)
PL (1) PL2533638T3 (es)
RS (1) RS54618B1 (es)
RU (1) RU2585763C2 (es)
SI (1) SI2533638T1 (es)
SM (1) SMT201600135B (es)
WO (1) WO2011100433A1 (es)
ZA (1) ZA201205374B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099978A1 (en) 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Chromone inhibitors of s-nitrosoglutathione reductase
SI2533638T1 (sl) 2010-02-12 2016-05-31 Nivalis Therapeutics, Inc. Novi inhibitorji S-nitrozoglutation reduktaze
US8921562B2 (en) 2010-10-08 2014-12-30 N30 Pharmaceuticals, Inc. Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors
EP2651223A4 (en) 2010-12-16 2015-07-22 Nivalis Therapeutics Inc NOVEL BICYCLIC AROMATIC COMPOUNDS SUBSTITUTED AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
EP2870138B1 (en) 2012-07-06 2018-08-22 Genentech, Inc. N-substituted benzamides and methods of use thereof
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016191312A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP4017563A4 (en) * 2019-08-23 2024-04-03 Nota Laboratories Llc NITRIC OXIDE GENERATION SYSTEMS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
WO1997031007A1 (en) 1996-02-21 1997-08-28 Glycomed Incorporated SIALYL LEWISx MIMETICS CONTAINING FLAVANOID BACKBONES
EP0885211B1 (en) * 1996-03-05 2004-12-29 Sterix Limited Compounds with a sulfamate group
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
KR20000001793A (ko) * 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2001080855A1 (en) 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US7049308B2 (en) 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US20030181510A1 (en) 2002-03-19 2003-09-25 Robert Baker Inhibition of muscle regeneration following myectomy
NZ537366A (en) 2002-06-27 2007-12-21 Endowment For Res In Human Bio Compounds useful for the inhibition of ALDH
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US8138165B2 (en) 2002-10-22 2012-03-20 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
US20050014697A1 (en) 2003-06-04 2005-01-20 Stamler Jonathan S. Compositions and methods for modulating S-nitrosoglutathione reductase
CN1241921C (zh) 2003-07-09 2006-02-15 东华大学 含氟异黄酮衍生物、制造方法及其用途
MXPA06011637A (es) 2004-04-08 2007-05-04 Aryx Therapeutics Materiales y metodos para el tratamiento de trastornos de la coagulacion.
EP1735296B1 (en) 2004-04-08 2009-12-09 Aryx Therapeutics Materials and methods for treating coagulation disorders
CA2592001A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-ht receptor ligands
CN101171241A (zh) 2005-03-11 2008-04-30 密执安州立大学董事会 抗细胞凋亡的bcl-2家族成员的色烯-4-酮抑制剂及其应用
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US20080032995A1 (en) * 2006-07-27 2008-02-07 Jeff Zablocki Aldh-2 inhibitors in the treatment of drug addiction
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
WO2009026657A1 (en) 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
EP2229451A4 (en) * 2007-12-13 2012-06-13 Univ Indiana Res & Tech Corp MATERIALS AND METHOD FOR INHIBITING ANIMALS S NITROSOGLUTATHION REDUCTASE
WO2010107476A1 (en) 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
SI2533638T1 (sl) 2010-02-12 2016-05-31 Nivalis Therapeutics, Inc. Novi inhibitorji S-nitrozoglutation reduktaze
WO2011099978A1 (en) 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Chromone inhibitors of s-nitrosoglutathione reductase
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors

Also Published As

Publication number Publication date
KR20120138746A (ko) 2012-12-26
US20120289555A1 (en) 2012-11-15
US9187447B2 (en) 2015-11-17
US8759548B2 (en) 2014-06-24
CN102869255B (zh) 2016-08-31
SI2533638T1 (sl) 2016-05-31
CN102869255A (zh) 2013-01-09
PL2533638T3 (pl) 2016-08-31
DK2533638T3 (en) 2016-04-25
RU2012132692A (ru) 2014-02-10
ZA201205374B (en) 2013-09-25
US9707212B2 (en) 2017-07-18
JP2013519680A (ja) 2013-05-30
BR112012019529A2 (pt) 2019-09-24
IL220956A (en) 2015-09-24
EP2533638B1 (en) 2016-02-10
JP5878484B2 (ja) 2016-03-08
SMT201600135B (it) 2016-07-01
HUE029012T2 (en) 2017-02-28
AU2011215833B2 (en) 2015-07-09
US20140275185A1 (en) 2014-09-18
CA2787633A1 (en) 2011-08-18
HK1178742A1 (zh) 2013-09-19
EP2533638A4 (en) 2013-06-05
EP2533638A1 (en) 2012-12-19
AU2011215833A1 (en) 2012-08-30
US20160045478A1 (en) 2016-02-18
WO2011100433A1 (en) 2011-08-18
RS54618B1 (en) 2016-08-31
JP2016040285A (ja) 2016-03-24
HRP20160450T1 (hr) 2016-05-20
RU2585763C2 (ru) 2016-06-10

Similar Documents

Publication Publication Date Title
ES2565345T3 (es) Nuevos inhibidores de la reductasa de s-nitrosoglutatión
CA3154618A1 (en) Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
ES2610425T3 (es) Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico
ES2542728T3 (es) Composiciones farmacéuticas que tienen la biodisponibilidad deseable
US9402913B2 (en) Cyclosporine A steroid conjugates
ES2691805T3 (es) Medicamento para el tratamiento de una enfermedad ocular
ES2966093T3 (es) Formulación farmacéutica que contiene un derivado de quinolona
US9636376B2 (en) Stable compositions of peptide epoxy ketones
ES2351365T3 (es) Composición farmacéutica estabilizada.
ES2326471T3 (es) Composicion de uso topico que comprende un ciclofructano, un vehiculo y un farmaco.
TW202200121A (zh) 治療方法
AU2021201251B2 (en) Antimicrobial compounds, compositions, and uses thereof
JP6800264B2 (ja) ジブチルヒドロキシトルエンの安定化方法
ES2600469T3 (es) Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
KR20100045513A (ko) 감염의 치료 또는 제어를 위한, 퀴놀론을 포함하는 조성물 및 방법
ES2693122T3 (es) Composición
US20230102999A1 (en) Deuterated niclosamide
WO2004096279A1 (ja) 注射用組成物
JP6073202B2 (ja) 静脈におけるウイルスの治療
ES2618374T3 (es) Composiciones y métodos para mejorar la absorción de glucosa
CA3238758A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
ES2864735T3 (es) Formulaciones oftálmicas que contienen gamma-lactamas sustituidas y métodos para el uso de las mismas
ES2349410T3 (es) Formulación farmacéutica de agente de leucotrieno b4 (ltb4) estabilizado.
JP2009538822A5 (es)
TW201106961A (en) Ipamorelin diacetate injection and infusion solutions